Business
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Kansas City, KS- SEKISUI XenoTech announces the promotion of Dr. Darren Warren, PhD to President and Chief Executive Officer.
MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair, announced the advancement of its ongoing collaborative research project with the United States Army Institute of Surgical Research in the area of burn wound healing.
Souderton, PA, U.S., 28 January 2020 – Almac Clinical Services, part of the global contract pharmaceutical development and manufacturing organization the Almac Group, is delighted to invite participants from the Pharma & Biotech industries to join its West Coast Lunch and Learn Workshop Series.
Piramal Enterprises Limited’s Pharma Solutions business, a leading Contract Development and Manufacturing Organization, announced plans to expand its Aurora facility in Canada with the addition of a new state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients.
Krystal Biotech and Foghorn Therapeutics are beginning 2020 with significant expansion projects.
China’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.
All three companies have invested millions in the facilities to expand their global footprint.
The company based the decision on safety information after unexpected serious adverse events, including one patient death in its Phase IIb CATALYST trial.
The U.S. Department of Justice has leveled more charges against members of the U.S. science community who have alleged ties to China.
GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus.